WuXi AppTec acquires biology focused CRO

Chinese research and development platform company WuXi AppTec said today it has acquired HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO).

After completion of acquisition, financial terms of which were not disclosed, HD Biosciences will become a wholly-owned subsidiary of WuXi, and will continue to focus on growing its core competences and providing greater services. The acquisition will further strengthen WuXi's R&D capability from target validation to lead discovery and optimization, improving and expanding WuXi's open-access enabling service platform.

Founded in 2002, HD Biosciences is headquartered in Shanghai with operating facilities in Beijing and San Diego, USA. As a leading biology and preclinical service provider, its plate-based pharmacology & screening capability and AGM based target validation are industry leading platforms with great reputation. The company also provides hit identification, lead discovery, in vivo pharmacology and other related services.